Demonstrates sensitive early detection of neuropathy in cancer patients, suggesting chemotherapy dosage adjustments.
Background: A significant proportion of patients with cancer experience symptoms of sensory nerve damage from chemotherapy known as chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a major dose-limiting toxicity of many chemotherapeutic regimens. Early detection and quantification of CIPN is a significant challenge. It is hypothesized that the non-invasive, non-painful, Pressure-Specified Sensory Device (PSSD) will be a sensitive and specific tool for measuring CIPN. If CIPN can be detected early, then Oncology might be able to alter the drug regimen, and if CIPN persisted, then lower extremity nerve decompression would be possible. Methods: A prospective cohort of patients receiving chemotherapy were referred by their Oncologist. During the administration of their IV chemotherapy, the patient had PSSD testing of the index, little finger and finger and big toe pulp. Quality-of-life outcome instruments QLQ-CIPN20, and the Michigan Neuropathy Symptom Score Instrument were administered. Each patient was evaluated for the presence of a Tinel sign at known sites of nerve entrapment. Inclusion criteria were patients receiving neurotoxic chemotherapy (Vincristine, Taxol, or Cisplatin). Results: Thirteen patients were enrolled. There were no complications from neurosensory testing. The PSSD was 80% sensitive and 100% specific identifying symptomatic neuropathy, p < .014, Chi Square and p < .05 using the Fisher exact test. PSSD testing became abnormal prior to the patient becoming symptomatic and prior to the presence of a positive Tinel sign. Conclusion: Non-invasive and non-painful neurosensory testing is feasible to do during chemotherapy IV infusion. This can identify changes in peripheral nerve function that correlate with a patient’s symptoms and therefore can be used by the Oncologist to alter the patient’s chemotherapy dosage, limiting chemotherapy toxicity, and make recommendations for surgical decompression if nerve compression persists.
No takes yet. Share an insight, caveat, or question.
Oles et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: